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Abstract 
A field trial was conducted in a camel brucellosis-free herd to evaluate antibody response to the Brucella melitensis 
Rev.1 vaccine   in camels and assess shedding of the vaccine strain in milk. Twenty eight camels were divided into 
four groups according to their age and vaccination route. Groups A (n=3) and B (n=3) consisted of non-pregnant 
lactating female camels, vaccinated through subcutaneous and conjunctival routes, respectively. Groups C (n=10) 
consisted of 8-11 months old calves vaccinated through conjunctival route. The rest of the herd (n=12) composed of 
female and young camels were not vaccinated and were considered as the control group. Each animal from groups 
A, B and C was given the recommended dose of 2 x 109 colony forming units of Rev.1 vaccine irrespective of age or 
route of vaccination. Blood samples were collected from all the animals at the time of vaccination and at weekly,   
bi-weekly  and  monthly  interval  until  32  weeks  post  vaccination  and  from  controls  at  weeks  8  and  24.  The 
serological tests used were modified Rose Bengal Test, sero-agglutination test, and an indirect Enzyme Linked 
Immunosorbent Assay. Milk samples were collected from all vaccinated female camels and tested for the presence 
of Rev.1 vaccine strain. Most vaccinated animals started to show an antibody response at week 2 and remained 
positive  until  week  16.  By  week  20  post-vaccination  all  animals  in  the  three  groups  were  tested  negative  for 
Brucella antibodies. Bacteriological analysis of milk samples did not allow any isolation of Brucella melitensis. All 
samples were found Brucella negative in PCR analysis. The results of this study indicate that the Rev.1 vaccine 
induces seroconversion in camels. Rev.1 vaccine strain is not excreted in the milk of camels. These findings are 
promising as to the safe use of the Rev.1 vaccine in camels.  
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Introduction 
Dromedary  (Camelus  dromedarius)  farming  is 
important  throughout  countries  of  North  Africa,  the 
Horn  of  Africa  and  the  Middle  East,  not  only  as  a 
transport means for nomads but also as leather, wool, 
milk and meat provider for local consumption, as well 
as  an  important  sport  and  tourism  resource  in  the 
Arabian  Gulf  countries.  Despite  the  growing 
importance  of  camel  farming,  the  epidemiological 
features  and  investigations  of  infectious  disease 
problems have not been the focus of many studies in 
this animal species (Tibary et al., 2006).  
In  particular,  brucellosis  in  camels  has  not  received 
much attention from researchers and scientists (Abbas 
and Agab, 2002; Gwida et al., 2012). Camelids are not 
known to be primary nor main hosts of Brucella spp., 
but  they  are  susceptible  to  both  B.  abortus  and 
Brucella  melitensis  (B.  melitensis)  (Cooper,  1991; 
Abbas and Agab, 2002; Gwida et al., 2012). Yet, in 
addition  to  causing  abortions,  stillbirths  and  other 
clinical  signs  in  camels,  brucellosis  is  a  zoonotic 
disease which can spread and cause disease to humans 
especially those in contact with infected animals and 
those  consuming  milk  or  dairy  products  usually 
manufactured  using  traditional  methods  (Cooper, 
1991; Benkirane, 2006).  
Brucella  infection  rate  and  the  contribution  of 
infecting  Brucella  species  in  a  given  country  are 
correlated  with  the  prevalence  of  brucellosis  in  the 
primary  animal  host  species  i.e:  cattle,  sheep,  and 
goats,  respectively  for  B.  abortus  and  B.  melitensis. 
However, in the last two decades, there has been an 
apparent increase in the prevalence of brucellosis in 
small ruminants in many countries in Central Asia and 
Eastern  Europe  because  of  various  sanitary  and 
socioeconomic  reasons  including  the  breakdown  of 
disease  control  systems  in  many  former  soviet 
republics  (Jackson  et  al.,  2007;  Ward  et  al.,  2012). 
The  situation  of  brucellosis  in  Middle  East  is  also 
worsening (Pappas et al., 2006) presumably because 
of  lack  of  strict  disease  control  and  surveillance 
programmes.  B.  melitensis  emerged  as  a  causative 
agent of bovine and cameline brucellosis, especially in 
some  Middle  Eastern  countries  (Benkirane,  2006) 
when they are pastured together  with infected sheep 
and  goats.  Milk  from  infected  camels  represents  a http://www.openveterinaryjournal.com 
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major source of infection that is underestimated in the 
Middle East (Musa et al., 2008). B. melitensis biovar 3 
is the most widespread source of infection in camels in 
the Middle East, and it has  been isolated  in Sudan, 
Jordan and Egypt. B. melitensis biovar 1 has also been 
isolated  in  Iran,  Kuwait  and  Libya.  The  reported 
prevalence varied between a low prevalence (2-5%) in 
nomadic  or  extensively  kept  camels  to  a  high 
prevalence  (8-15%)  in  camels  kept  intensively  or 
semi-intensively (Abbas and Agab, 2002). 
The B. melitensis Rev.1 vaccine (Rev.1 vaccine) is the 
best vaccine available for the control of brucellosis in 
small ruminants (Blasco, 1997, 2006; Munoz et al., 
2008). In camels, although vaccination with the B. 
melitensis Rev.1 strain has been occasionally applied 
(Radwan  et  al.,  1995),  its  innocuity  and  protective 
efficacy  have  been  poorly  documented.  With  the 
emergence of B. melitensis in camels, it is expected 
that affected countries with a big camel industry will 
use  the  Rev.1  vaccine  to  protect  their  herds  against 
this  infection.    The  Rev.1  vaccine  is  infectious  to 
humans  and  its  use  in  lactating  females  including 
camels  could  be  a  hazard  for  consumers  through 
consumption of unpasteurized milk. A limited number 
of  confirmed  cases  have  been  reported  as  being  of 
sheep and goat origin (Blasco and Diaz, 1993; Banai 
et al., 1995; Bardenstein et al., 2002) and others of 
camel origin (Ben Shimol et al., 2012; Gwida et al., 
2012).  
The present study was conducted to evaluate, in a field 
trial,  the  innocuity  and  immune  response  to  Rev.1 
vaccine in camels and assess the bacterial shedding of 
the Rev.1 vaccine strain in the milk of female camels. 
Materials and Methods 
Animals  
Twenty-eight local Guerzini “type” camels included in 
this  field  study  were  obtained  from  a  “brucellosis-
free”  state  owned  farm  located  in  the  region  of 
Laayoune, south Morocco during the period between 
January  2012  and  July  2012.  Study  animals  were 
either females aged 5-11 years or calves aged between 
8-11 months. Brucellosis was never reported and there 
is  no  history  of  brucellosis  vaccination  in  the 
Laayoune  region.  Before  the  start  of  the  trial,  all 
animals  were  subjected  to  a  thorough  clinical 
examination.  Milk  samples  from  the  female  camels 
and  blood  samples  from  all  animals  were  taken  for 
testing before the experiment. 
Treatment groups and vaccination protocols 
The  B.  melitensis  Rev.1  vaccine  (ND  Ocurev;  CZV 
Porriño.  Spain)  ready  for  conjunctival  delivery  was 
used  in  this  experimental  study.  The  dose 
administered via the conjunctiva was two drops (50 to 
60 microliters) per animal in the  same eye.  For the 
subcutaneous  route,  the  vaccine  vial  content  was 
diluted  in  40  ml  sterile  phosphate  buffer  saline 
(pH=7.4) and a dose of 2 ml inoculated to each animal 
at the elbow. The colony forming units (CFU) counts 
and the assessment of the absence of contamination 
and  Rev.1  vaccine  dissociation  were  performed  on 
Trypticase  Soy  Agar  before  and  after  vaccination 
following standard procedures (Alton et al., 1988). 
Animals were assigned to three groups based on age, 
sex and lactation status. Groups A (n=3) and B (n=3) 
consisted  of  non-pregnant  lactating  female  camels, 
vaccinated  with  Rev.1  vaccine  through  conjunctival 
and  subcutaneous  routes,  respectively.  Groups  C 
(n=10) consisted of 8-11 months old calves similarly 
vaccinated through conjunctival (C) route. The rest of 
the animals in the herd, which consisted of 12 adult 
dry female camels, were not vaccinated and therefore 
considered  as  control  group.  The  selection  of  study 
animals and design of treatment groups were decided 
according  to  the  availability  of  animals  rather  than 
random selection.  
After  vaccination,  all  animals  were  reared  together 
with no restriction of movements between vaccinated 
and  unvaccinated  animals.  Animals  were  observed 
daily during the first 15 days post-vaccination for any 
adverse reactions.  
Serological testing  
Blood  samples  from  all  vaccinated  animals  were 
collected  before  vaccination,  and  subsequently  on  a 
weekly  basis  for  the  first  8  weeks,  biweekly  from 
week 8 to 16 and every 4 weeks from week 16 to 32. 
Blood  was  also  collected  from  control  animals  on 
weeks  8  and  24  in  order  to  detect  any  possible 
horizontal  passage  of  the  vaccine  strain  bacteria 
between  vaccinated  and  unvaccinated  animals.  All 
samples were centrifuged locally and refrigerated until 
ready for transport to the laboratory. 
Collected  sera  were  evaluated  for  antibodies  to  the 
Rev.1 vaccine strain by three serological methods, the 
modified  Rose  Bengal  test  (mRBT),  a  commercial 
sero-agglutination  test  (SAT),  and  a  customized 
indirect ELISA (iELISA). Serum samples taken from 
control  animals  were  also  used  for  the  design  and 
standardization of the iELISA test.  
A commercial Rose Bengal antigen (Synbiotics) was 
used in a modified test with 25µL antigen and 75µL 
serum as described by Blasco  et al. (1994). Results 
were considered positive for RB when there was any 
degree of visible agglutination. 
A  commercially  available  sero-agglutination  test 
(SAT)  antigen  (Synbiotics)  was  used  to  test  the 
samples according to the manufacturer's instructions. 
The SAT antigen was diluted ten-fold in phenicated 
physiological  water  (0.5%)  and  distributed  in  clean 
serology  tubes  together  with  test  sera  at  dilutions 
ranging from 1/10 to 1/320 and a constant volume of 
0.5 ml for both reactants. Due to the lack of a gold 
standard positive camel serum at the WHO/FAO/OIE http://www.openveterinaryjournal.com 
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reference  laboratory  for  brucellosis,  the  Veterinary 
Laboratories  Agencies,  Weybridge,  agglutinations  at 
the dilutions of 1/20 and beyond were considered as 
positive. 
An  iELISA  was  developed  and  standardized  as 
follows:  The  antigen  (B.  melitensis  16M  S-LPS 
obtained by phenol extraction) was used at 2.5 µg/ml. 
Sera  were  diluted  from  1/5  to  1/200.  The  highest 
differences between the optical density (OD) readings 
before  vaccination  and  of  the  unvaccinated  groups 
(considered as gold standard negative population) and 
three weeks after vaccination (maximal response, and 
considered as the gold standard positive population) 
was  evidenced  using  the  1/5  serum  dilution.  As 
conjugates,  both  recombinant  protein  G  and  A/G 
(from Pierce) were tested at concentrations ranging 2-
3  µg/ml.  The  best  resolution  using  the  same  gold 
standard sera than above was obtained with the protein 
A/G at 3 µg/ml. The substrate was ABTS and the OD 
was assessed at 15, 20, 25 and 30 minutes at 405 nm. 
Antigen solution in Phosphate buffer solution (PBS) 
(2.5  µg/ml)  was  adsorbed  to  plastic  plates  (100  µl/ 
well)  after  overnight  incubation  at  4ºC.  Duplicate 
serum dilutions (1/5) were incubated (100 µl/ well) at 
37ºC for 45 min. The working dilution (100 µl/ well of 
protein  A/G  at  3  µg/ml  in  PBS-Tween)  of  the 
conjugate was then incubated at 37ºC for 45 min, and 
the  reaction  revealed  with  100  µl/  well  of  ABTS 
substrate with readings (405 nm) at 15, 20, 25 and 30 
min. The mean OD was expressed as the percentage 
OD of a control serum. This test was performed only 
on  sera  collected  from  week  0  to  week  16  at  the 
Centro  de  Investigación  y  Tecnología 
Agroalimentaria, Saragossa Spain (CITA). 
Testing of milk samples 
Milk samples were collected twice weekly during the 
first eight weeks after vaccination. Milk samples were 
drawn  into  sterile  tubes  from  the  four  teats  of  the 
mammary gland. Milk samples from each animal were 
pooled  and  stored  at  4°C,  and  transported  to  the 
laboratory for immediate culture within a maximum of 
three  days  after  sampling.  The  creamy  layer  and 
deposit from each sample were collected and spread 
onto  the  Farrell  selective  medium  containing  a 
commercial  antibiotic  supplement  (Oxoid  Ref 
SR0209E) and the CITA medium used according to 
De Miguel et al. (2011). The plates  were  incubated 
during 10 days at 37oC and regularly observed for any 
growth. 
DNA extraction and PCR 
The Polymerase Chain Reaction (PCR) was performed 
as  described  by  Mayer-Scholl  et  al.  (2010)  at  the 
Brucellosis  Unit  of  the  Veterinary  Laboratories 
Agencies, Weybridge. Briefly, DNA samples extracted 
from milk samples from each animal and also from the 
samples from which suspect colonies grew were tested 
by  a  multiplex  PCR  for  the  detection  of  Brucella 
species, including B. melitensis and the Rev.1 vaccine 
strain. 
Results 
There  were  no  clinical  signs  attributable  to  vaccine 
administration  observed  in  any  of  the  vaccinated 
animals. Slight temperature rises (ca. 1oC) occurred at 
day 7 post-vaccination in  most animals,  which look 
healthy for the rest of the field trial. 
Serological testing  
All sera taken from control animals tested negative for 
antibodies  to  the  Rev.  1  vaccine  for  all  three 
serological tests, confirming the absence of Brucella 
spp. in the study location. Post-vaccination antibodies 
using mRBT are shown in Table 1. All animals of the 
three groups were antibody positive from week 2 to 
week 10 after which sero-positivity began to decline. 
At week 20 and beyond, all sera became negative.  
 
Table 1. Number of seropositive camels in the treatments 
groups  (A,  B  and  C)  by  the  modified  Rose  Bengal  Test 
following vaccination with the B. melitensis Rev. 1 vaccine. 
 
week  Group A 
(n=3) 
Group B 
(n=3) 
Group C 
(n=10) 
Total 
positive 
0  0  0  0  0 
1  2  0  0  2 
2  3  3  10  16 
3  3  3  10  16 
4  3  3  10  16 
5  3  3  10  16 
6  3  3  10  16 
7  3  3  10  16 
8  3  3  10  16 
9  -  -  -  - 
10  3  3  9  15 
11  -  -  -  - 
12  3  3  6  12 
13  -  -  -  - 
14  3  3  4  10 
15  -  -  -  - 
16  3  3  3  9 
20  0  0  0  0 
Group A = 3 female camels vaccinated conjunctivally. Group B = 3 
female  camels  vaccinated  subcutaneously.  Group  C  =  10  camel 
calves vaccinated conjunctivally. 
 
Post-vaccination seroconversion (with a threshold of 
≥1/20)  was  detected  using  the  SAT  in  four  animals 
from  week  2,  then  in  all  animals  from  week  3 
onwards.  Detection  of  antibodies  began  to  decline 
from week 16 until weeks 20 and 24 when only one 
animal from group B remained positive. Most animals 
showed high titers 5 or 6 weeks post-vaccination in 
the three treatment groups (Figure 1). http://www.openveterinaryjournal.com 
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Fig. 1. Mean antibody titers by Serum Agglutination Test in 
the  treatment  groups  (A,  B  and  C)  following  vaccination 
with  B.  melitensis  Rev.  1  vaccine.  Group  A  =  3  female 
camels  vaccinated  conjunctivally.  Group  B  =  3  female 
camels  vaccinated  subcutaneously.  Group  C  =  10  camel 
calves vaccinated conjunctivally. 
  
Figure  (2)  provides  the  temporal  evolution  of  sero- 
conversion  detected  using  the  iELISA  test  for  each 
treatment group. Most vaccinated animals in the three 
groups started to show an antibody response at week 2 
which remained at high levels until week 16. Samples 
were not tested beyond week 16.  
The seroconversion as measured by the three tests was 
similar  with  slight  delay  in  terms  of  persistence  of 
antibodies tested by SAT in group B where animals 
were vaccinated subcutaneously.  
Analysis of milk samples   
All  milk  samples  were  culture  negative  on  both 
culture media (Farrell’s and CITA) and found to be 
negative  in  PCR  assay  for  B.  melitensis  and  Rev.1 
vaccine strain. The use of two distinct culture media is 
justified by the fact that nalidixic acid and bacitracin 
contained in the Farrell’s have some inhibitory effects 
on the growth of Brucella, particularly B. melitensis; 
therefore,  other  culture  media  such  as  the  CITA 
medium  should  be  used  simultaneously  with  the 
Farrell’s to increase the likelihood of isolating smooth 
Brucella colonies (De Miguel et al., 2011).  
Discussion 
The administration of the Rev.1 vaccine in adult and 
young camels has not revealed any significant adverse 
reaction  in  vaccinated  animals.  This  confirms 
observations  from  the  field  reports  in  Oman  (El 
Idrissi, personal communication) where Rev.1 vaccine 
has been safely used in camels.  
According  to  the  manufacturer,  the  vaccine  used  in 
this trial meets the standards especially with regard to 
the possible smooth-rough dissociation that might lead 
to vaccine inefficacy. It is worth noticing that, in view 
of  the  smooth-rough  dissociation  drawback,  it  was 
recently  suggested  that  some  genetic  modifications 
may stabilize the Rev.1 strain (Mancilla et al., 2013). 
 
 
Fig. 2. Antibody titers by iELISA in the treatment groups 
(A, B and C) following vaccination with the B. melitensis 
Rev. 1 vaccine. (A): Antibody response in Group A (3 she-
camels, vaccinated cunjunctivally). (B): Antibody response 
in group B (3 she-camels, vaccinated subcutaneously). (C): 
Antibody response in group C (10 young calves, vaccinated 
cunjunctivally). 
 
Antibody  response  to  vaccination  as  measured  by 
mRBT,  SAT  and  iELISA  showed  a  standard 
seroconversion  comparable  to  the  serological 
evolution  reported  in  other  animal  species  such  as 
cattle, sheep and goats. Although none of these tests 
has been evaluated in camels, they have been widely 
used  to  assess  the  serological  response  to  Brucella 
infection  in  camels  (Abbas  and  Agab,  2002).  The 
modified Rose Bengal test (Blasco et al., 1994) and an 
iELISA  were  found  to  be  more  sensitive  than  the 
conventional Rose Bengal and CFT when used to test 
animals  for  B.  melitensis  infection  (Ferreira  et  al., 
2003).    This  justified  the  use  of  these  two  tests  in 
addition to SAT in order to evaluate the serological 
response to Rev.1 vaccine in camels. 
Given  the  late  reproduction  maturity  and  mating  in 
female  camels  (ca.  three  years  of  age),  on  the  one 
hand,  and  the  duration  of  post-vaccination 
seropositivity  not  exceeding  six  months  whatever 
route of vaccination was used and irrespective of age, http://www.openveterinaryjournal.com 
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on  the  other  hand,  one  does  not  have  to  be  strict 
concerning  the  age  at  which  vaccination  should  be 
administered.  Thus,  should  the  above  finding  be 
corroborated through more extensive studies, 12 to 18 
months could be the age at which vaccination is to be 
performed.  
The number of animals in each subset is too low and 
does  not  allow  for  any  statistical  interpretation. 
However, it appears that adults react more profoundly 
than  young  animals,  which  is  in  line  with  reported 
findings in sheep and goats (Fensterbank et al., 1982; 
Blasco, 2006). It is noteworthy that, on week 20, all 
sera became negative with mRBT and, on week 24, 
they were all negative when tested with SAT. 
The role of the route of vaccination in the persistence 
of Brucella antibodies could not be assessed given the 
small number of animals in each group. It is known 
that,  in  small  ruminants,  antibodies  persist  much 
longer  when  animals  are  vaccinated  subcutaneously 
than conjunctively (Zundel et al., 1992; Verger, 1995).  
The  subcutaneous  route  of  Rev.1  vaccine 
administration remains widely used in most countries, 
sometimes  at  so-called  "reduced  doses",  although  it 
was  demonstrated  that  the  conjunctival  route  is 
preferable both in terms of safety (reduction of post-
vaccination  abortions  in  emergency  situations  when 
pregnant animals are vaccinated) and with respect to 
Brucella  excretion  in  the  milk  (Blasco,  1997).  This 
was  demonstrated  in  small  ruminants  but  never  in 
camels and inference is made in this work assuming 
that camels will react alike small ruminants. However, 
it has  not been proven that  reducing the  number of 
CFU per vaccine dose would preserve its full potency 
or confer it a better safety (Blasco, 1997). Thus, only 
the conventional dose of 1 to 2x109 CFU was used in 
this work.  
The absence of shedding of the vaccine strain in milk 
as  tested  by  the  lack  of  bacterial  isolation  up  to  8 
weeks was confirmed by PCR that failed to detect any 
trace of Brucella DNA in tested samples. Shedding of 
the Rev.1 vaccine strain through the udder following 
vaccination  has  occasionally  been  reported  in  sheep 
and  goats.  When  used  in  pregnant  ewes,  the  Rev.1 
strain may lead to abortion and the excretion of the 
bacterium  in  the  milk.  In  a  field  experiment,  a  few 
goats  excreted  Rev.1  strain  in  milk  for  44  and  49 
weeks post-abortion and in one ewe out of 19 (ca. 5 
per cent) the excretion persisted for 6  months post-
abortion  (Zundel  et  al.,  1992).  However,  when 
vaccination was performed in non-pregnant goats, no 
vaccine  strain  was  isolated  in  the  milk  (Jones  and 
Marly,  1975).  Similar  results  have  been  obtained  in 
cows vaccinated with a reduced dose of Rev.1 vaccine 
(Garcia-Carrillo, 1980). 
The  only  available  study  on  the  control  of  camel 
brucellosis was conducted in Saudi Arabia (Radwan et 
al., 1995). No Brucella organisms were recovered in 
the  Farrell’s  medium  from  repeated  udder  secretion 
samples  from  all  vaccinated  milking  camels.  This 
finding is in line with our results though one should 
consider  a  higher  number  of  vaccinated  animals  to 
confirm the absence of Brucella excretion in the milk. 
Conclusion 
The present work showed that, when female  camels 
were  vaccinated  against  brucellosis  with  the  Rev.1 
vaccine  administered  either  subcutaneously  or 
conjunctively, this did not result in the shedding of the 
vaccine  strain  in  the  milk  throughout  a  follow-up 
period of up to eight weeks. However, these results 
were obtained with only a small number of animals 
that  is  not  significantly  representative.  Should  this 
finding  be  confirmed  through  a  study  with  more 
animals,  it  would  be  concluded  that  the  milk  from 
vaccinated  animals  does  not  yield  Brucella.  This 
would  be  a  good  argument  in  favor  of  vaccinating 
adult  camels  in  case  it  is  required,  given  the  milk 
consumption habit of camel keepers and their families 
drinking  raw  milk  from  the  udder.  It  is  also 
recommended  to  verify  these  finding  using  a  larger 
number  of  animals  to  refine  the  estimation  of  the 
duration of the post-vaccinal seroconversion. Finally, 
the  most  critical  future  step  to  be  undertaken  is  to 
evaluate the vaccine safety in pregnant female camels 
as well as the potency through a vaccination-challenge 
trial conducted on a sufficient number of animals.  
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